Cardiovascular risk changes after lipid lowering medications: are they predictable? (Q34038507)

30 July 2017

1 reference

title

Cardiovascular risk changes after lipid lowering medications: are they predictable? (English)

1 reference

ORCID Public Data File 2021

30 July 2017

1 reference

author name string

Sirtori CR

1

1 reference

30 July 2017

Calabresi L

2

1 reference

30 July 2017

Marchioli R

3

1 reference

30 July 2017

Rubins HB

4

1 reference

30 July 2017

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

152

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

1-8

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Evidence based medicine: what it is and what it isn't

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Application of evidence from randomised controlled trials to general practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

The number needed to treat: a clinically useful measure of treatment effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

New developments in the treatment of low high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

EVIDENCE-BASED MEDICINE CRITERIA APPLIED TO HYPOLIPIDEMIC AND ANTIHYPERTENSIVE DRUG TRIALS: IS DRUG EFFICACY ALWAYS THE SAME?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Coronary risk estimation and treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

A simple computer program for guiding management of cardiovascular risk factors and prescribing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Lipid-lowering interventions in angiographic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Beyond LDL cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Triglycerides are more important in atherosclerosis than epidemiology has suggested

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Low-density lipoprotein-independent effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900551-7

10.1016/S0021-9150(00)00551-7

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference